Added MNTA. Same price as pre-approval of Copaxone biosimilar. Started RXDX. Good proof of concept at ASCO 2015, but price now came down enough Started ACAD. Derisked now as NDA forNuplazid was finally filed. Started TGTX. Low market cap and price went back to before SPA of p3.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.